Human papillomavirus (HPV) is the necessary cause of cervical cancer, which is the second most common cancer in women worldwide with over 493,000 new cases occurring in 2002. High vaccine efficacy ...

The APAC human papillomavirus (HPV) vaccine market is expected to grow from US$ 567.57 million in 2022 to US$ 826.34 million by 2028; it is estimated to grow at a CAGR of 6.5% from 2022 to 2028.

New data from the CDC’s 2021 National Immunization Survey estimated that 80.9% of teens in Utah have received their first dose of the human papillomavirus vaccine.

The vaccine is offered each year to boys and girls aged 12 to 13 to help protect them against catching the infection which causes nearly all cervical cancers and is linked to mout ...

Human papillomavirus (HPV) vaccines have long been central to reducing the global incidence of HPV‐associated cancers and benign lesions. Traditional vaccines, based on virus‐like particles ...

I currently test for human papillomavirus (HPV) DNA as a marker for HPV infection. With the advent of the HPV vaccine, how will clinicians be able to ...

For her doctoral dissertation, Senior Planning Officer Idil Hussein studied the intentions of Finnish parents in terms of allowing their children to have human papillomavirus (HPV) and influenza ...

National Cancer Registry reports an estimated 641 cases of new HPV-associated cancers diagnosed and 196 cancer deaths every ...

The controversial vaccination for the most common sexually transmitted virus, human papilloma virus (HPV) — which has been available for girls' use since 2006 — is once again becoming contentious as ...

Vaccination for human papillomavirus (HPV) is effective against anal HPV infection in certain populations, according to a meta-analysis in The Journal of Infectious Diseases.. Researchers ...

Human Papillomavirus (HPV)-induced Cancers: First Patient Enrolled in Phase I/IIa Clinical Trial for Lenti-HPV-07, the TheraVectys’ Therapeutic Vaccine Candidate Against Oropharyngeal and ...

UKHSA data from January 2025 showed that school HPV vaccine uptake in England remains below pre-pandemic levels and continues to decline. In the 2023-2024 academic year, just 72.9% of Year 8 girls ...